.Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BB07_Glipizide.Glipizide_1 .Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BB07_Glipizide.Glipizide_1| name: | Glipizide_1 |
| ATC code: | A10BB07_1 | route: | oral |
| n-compartments | 2 |
Glipizide is an oral sulfonylurea antidiabetic drug used in the management of type 2 diabetes mellitus. It stimulates insulin secretion by the pancreas and is approved for use worldwide.
Population pharmacokinetic study in adult patients with type 2 diabetes, reported as a two-compartment model.
Khan, H, et al., & Rasool, MF (2025). Clinical pharmacokinetics of glipizide: a systematic review. Expert opinion on drug metabolism & toxicology 21(1) 69–79. DOI:10.1080/17425255.2024.2402478 PUBMED:https://pubmed.ncbi.nlm.nih.gov/39267225
Kim, NT, et al., & Lee, SY (2022). Effects of CYP2C9*3 and *13 alleles on the pharmacokinetics and pharmacodynamics of glipizide in healthy Korean subjects. Archives of pharmacal research 45(2) 114–121. DOI:10.1007/s12272-021-01366-y PUBMED:https://pubmed.ncbi.nlm.nih.gov/34952963
Kirchheiner, J, et al., & Brockmöller, J (2005). Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance. Clinical pharmacokinetics 44(12) 1209–1225. DOI:10.2165/00003088-200544120-00002 PUBMED:https://pubmed.ncbi.nlm.nih.gov/16372821